In the Literature
In their effort to study the percentage of patients with AS and nr-axSpA who respond to treatment with NSAIDs as proposed by ASAS/EULAR recommendations, the researchers provided 100 patients (50 with AS and 50 with nr-axSpA) with a continuous regimen of NSAID therapy at the maximum recommended or tolerated dose for 4 weeks and then prospectively compared their responses.
- Pregnancy Outcomes in Ankylosing Spondylitis
- Prescribing Patterns for JIA in the United Kingdom
- Sifalimumab Is a Potential New Treatment Approach for Patients with Systemic Lupus Erythematosus
- Sleep Disturbances Lead to Cognitive Decline
- Alemtuzumab Demonstrates Superior Outcomes versus Interferon-ß-1a in Relapsing-Remitting Multiple Sclerosis
- Aprepitant Relieves Nausea Associated with Dihydroergotamine Use for Migraine
- Positive Effect of Hormone Therapy on Physical Function in Postmenopausal Women with Multiple Sclerosis
- Impact of Biologic DMARDs Treatment on Risk for Sepsis or Mortality in Patients with Rheumatoid Arthritis
- Skin Temperature Screenings for Progressive Rheumatoid Arthritis
- EULAR Revises Its Recommendations for the Management of Fibromyalgia
- Growing Burden of Arthritis in the United States
- Patients with Lupus at Risk for End-Stage Renal Disease
- Multiple Sclerosis Tops Neurology Drug Costs in Medicare Payments
- Considering a Patient's Immune Status May Improve Treatment Outcomes in Glioblastoma
- AAN Updates Its Quality Measures for Parkinson's Disease to Improve Patient Care
- Afatinib Superior to Gefitinib as First-Line Treatment for EGFR Mutation–Positive NSCLC
- Combination Chemotherapy plus Radiation Prolongs Survival in Low-Grade Glioma
- Less Frequent Lung Cancer Screening Warranted in Individuals with Negative Initial Screening
- Oncology Benchmarks Annual Report Shows New Patient Visits, Drug Spending Are Rising
- Personalizing Therapy for Patients with Multiple Myeloma
